The swamp is busy this weekend trying there level best to tamp down FDA expectations going into EOP2. What we do know is B for OM has shown statistically significant therapeutic benefit by decreasing the incidence of SOM. B oral rinse has low systemic absorption, FDA should love this aspect imo. We are going against a hugely unmet debilitating disease so for crying out loud why wouldn't FDA get excited about it as well as our licensing partner.

http://www.ipharminc.com/press-release/2018/9...treatments